InvestSMART

Oncosil Medical Limited (ASX:OSL)

ALERT: Price-sensitive ASX Announcement for OSL
Current share price for OSL : $1.400 0.6 (75%)+
Announcement
Release
3 Feb 2026 10:52AM
Price at Release
$0.800
Full Release
download
Summary
OncoSil Medical Limited, trading under the ASX code OSL, has issued a prospectus for a non-renounceable entitlement offer to raise up to approximately $2 million. The offer allows eligible shareholders to subscribe for 1 new share for every 6.4 shares held, at an issue price of $0.68 per share, along with 1 new option per new share. Additionally, a placement to sophisticated and professional investors aims to raise $6 million. The funds are targeted for investment in manufacturing, market access, clinical activities, and general working capital. Bell Potter Securities Limited is the underwriter, and new shares and options are expected to be issued by mid-March 2026. The document also highlights various investment risks, such as regulatory challenges, funding requirements, and market acceptance of the OncoSil device. The offer is underpinned by strategic goals to expand manufacturing capabilities and enhance clinical and market presence.
Key Points
  • Prospectus for non-renounceable entitlement offer by OncoSil Medical Limited.
  • Entitlement offer of 1 new share per 6.4 shares at $0.68 each.
  • Placement to raise $6 million with additional options for each new share.
  • Funds to support manufacturing, market access, and clinical activities.
  • Entitlement offer fully underwritten by Bell Potter Securities Limited.
  • New shares and options expected to be issued by 17 March 2026.
  • Investment risks include regulatory, funding, and market acceptance challenges.
  • Strategic focus on expanding manufacturing and enhancing market presence.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.